Summary of Use during Lactation

No information is available on the clinical use of lixisenatide during breastfeeding. Because lixisenatide is a large peptide molecule with a molecular weight of 4858 daltons, the amount in milk is likely to be very low and absorption is unlikely because it is probably destroyed in the infant's gastrointestinal tract. Until more data become available, lixisenatide should be used with caution during breastfeeding, especially while nursing a newborn or preterm infant.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Alternate Drugs to Consider

Acarbose, Glipizide, Glyburide, Insulin, Metformin, Miglitol

Substance Name

Lixisenatide

CAS Registry Number

320367-13-3

Drug Class

• Breast Feeding
• Lactation
• Hypoglycemic Agents
• Incretins
• Glucagon-Like Peptide-1 Agonists
• GLP-1 Agonists